Paper Details

  1. Home
  2. Paper Details

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.

Author: BowersBrian, DorinskyPaul, EmmettAmanda, KalbergChris, LiebermanAllen K, PearlmanDavid S, PepsinPamela J, RickardKathleen A, WhiteMartha V

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fluticasone propionate and salmeterol combination product (FSC) is more effective than montelukast for initial maintenance therapy in patients with persistent asthma. FSC led to greater improvements in asthma control, symptom-free days, rescue-free days, and quality of life scores compared to montelukast.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Asthma is a chronic disease characterized by inflammation and bronchoconstriction. Medications that are able to effectively treat both components are advantageous. OBJECTIVE: To compare the efficacy of an inhaled corticosteroid and a long-acting beta2-agonist combination product with a ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1081-1206(10)62001-7

データ提供：米国国立医学図書館（NLM）

Inhaled Corticosteroids and Long-Acting Beta2-Agonists: A Powerful Combination for Asthma Management

This study investigates the effectiveness of a combination therapy involving inhaled corticosteroids and long-acting beta2-agonists (FSC) in treating persistent asthma. The researchers compared the efficacy of FSC with that of montelukast, a leukotriene antagonist, in a group of patients with persistent asthma who were symptomatic while receiving only short-acting beta2-agonists. The goal was to determine which treatment option provided greater improvements in asthma control and patient satisfaction.

FSC: A Superior Treatment Option for Persistent Asthma

The results showed that FSC significantly improved lung function, reduced asthma symptoms, and increased symptom-free days compared to montelukast. Patients treated with FSC also experienced a greater improvement in quality of life and were more satisfied with their treatment. These findings suggest that FSC is a more effective treatment option for persistent asthma.

Asthma Management: Finding the Right Path to Relief

This research offers valuable insights into the management of persistent asthma, highlighting the effectiveness of combination therapy involving inhaled corticosteroids and long-acting beta2-agonists. The study underscores the importance of individualized treatment approaches and the need to consider a variety of options to find the most effective treatment for each patient.

Dr.Camel's Conclusion

Just as a camel navigates the desert with a combination of strength and endurance, patients with persistent asthma may require a combination of medications to achieve optimal control. This research highlights the potential of FSC to provide relief and enhance quality of life for individuals battling this chronic condition.

Date :
  1. Date Completed 2002-03-25
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

11868930

DOI: Digital Object Identifier

10.1016/S1081-1206(10)62001-7

Related Literature

Article Analysis
・Effective treatment of asthma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.